A Novel Strategy for Diagnosis of Esophageal Adenocarcinoma.

食管腺癌（EAC）是两种主要类型的食管癌之一， 每年全球死亡人数EAC诊断是使用侵入性的，昂贵的，有风险的， 易接近的程序，食管胃内窥镜检查（EGD）。因此，迫切需要更容易、更安全、 更便宜的EAC诊断策略。我们的新策略建立在EAC患者令人兴奋的初步数据基础上 涉及一种可吞咽、可回收的海绵胶囊装置， (JHU专利申请中）。Capsulomics是一家专门为该项目成立的新创业公司， 该诊断测定称为“EsoSAVE”，用于EAC检测。 第一阶段STTR申请包含三个具体目标，以实施这一战略。目标1将优化 并验证EsophaCap DNA提取程序。目标2将生成多参数统计模型 来进一步加强我们有前途的甲基化生物标志物。目标3将确认海绵中的EsoSAVE测试 来自正常和EAC患者的样品。这些目标将解决重要的科学问题， 同时推进EsoSAVE诊断测试走向商业化实施。

Esophageal adenocarcinoma (EAC) is one of two major types of esophageal cancer, which causes 509,000 deaths worldwide annually. EAC diagnosis is made using the invasive, expensive, risky, and not universally accessible procedure, esophagogastroduodenoscopy (EGD). Thus, there is a pressing need for easier, safer, cheaper strategies for EAC diagnosis. Our novel strategy builds on exciting preliminary data in EAC patients involves a swallowable, retrievable sponge capsule device combined with a DNA methylation biomarker panel (JHU patent pending). Capsulomics, a new startup established specifically for this project, will commercialize this diagnostic assay, termed “EsoSAVE,” for EAC detection. This Phase I STTR application contains three Specific Aims to implement this strategy. Aim 1 will optimize and validate the EsophaCap DNA extraction procedure. Aim 2 will generate a multi-parameter statistical model to further strengthen our promising methylation biomarkers. Aim 3 will validate the EsoSAVE test in sponge samples from normal and EAC patients. These Aims will address important scientific questions while simultaneously advancing the EsoSAVE diagnostic test toward commercial implementation.